Oct. 27 at 5:52 PM
$RVPH
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) is planning to market Brilaroxazine in the United States, Europe, China, and Japan.
- Brand name schizophrenia medications vary widely in price, with a 30-day supply potentially costing anywhere from around
$190 to over
$1.X,400
- The U.S. schizophrenia market was approximately
$2.X.84 billion in 2024 and is projected to grow to
$12.78 billion by 2032
- Brilaroxazine is being developed as a brand-name drug. Reviva Pharmaceuticals anticipates having exclusivity for Brilaroxazine until around 2045
- Reviva has stated its intent to develop brilaroxazine for other neuropsychiatric conditions beyond schizophrenia, including bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD).
- Inflammatory and cardiometabolic diseases: The company is also exploring the drug's potential in treating conditions such as psoriasis, pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF).